22
Calypso Biotech BV (Amsterdam/Geneva), a spin-out of Merck-Serono, which became company in residence at JLABS in Beerse, Belgium, said it will use the proceeds to push its anti-interleukin-15 (IL-15) antibody CALY-002 to Phase Ia studies in several autoimmune indications. IL-15 is an immune checkpoint cytokine that controls inflammation as well as survival of tissue-resident memory T cells, a population of immune cells that has been demonstrated to be involved in disease maintenance and recurrence.
Calypso Biotech has chosen to develop CALY-002 in Eosinophilic Esophagitis (EoE) as well as in other undisclosed auto-immune indications. EoE is a…